Subscription price determined for iZafe’s warrant TO 8 B

The subscription price for warrant TO 8 B iZafe Group AB (“iZafe” or “the Company”) has been set at SEK 3.30 in accordance with the applicable option terms. One (1) warrant TO 8 B entitles the holder to subscribe for one (1) B share in iZafe. Subscription of Class B shares with the support of warrants can take place from and including 4 December 2020 to and including 18 December 2020. If all warrants of series TO 8 B are exercised, the Company will receive SEK 9,445,000 before issue costs.

Conditions in summary

Subscription period: 4 – 18 December 2020 (subscription takes place through simultaneous cash payment).

Number of warrants: 2,862,129 warrants of series TO 8 B.

Subscription price: The holder of warrants has the right to subscribe for one new B share in iZafe for each warrant at the subscription price of SEK 3.30 per share.

Issue volume: When full exercise of all warrants, SEK 9,445,026 is added to iZafe.

Last day for trading in warrants: 16 December 2020.

About Us

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at investor.izafe.se.

Subscription price determined for iZafe's warrant TO 8 B